Beam Therapeutics, a biotechnology company developing precision genetic medicines based in Massachusetts has announced the appointment of Gopi Shanker, as its chief scientific officer.
A scientific leader with more than 20 years of drug development experience in novel genetic medicine modalities, Shanker will report to Giuseppe Ciaramella, president of Beam, who has broad oversight of Beam’s research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.
“Gopi’s extensive background of leading drug discovery and development efforts, including in the area of gene therapy, is impressive, and we look forward to applying that expertise to our current and future programs,” Ciaramella said.
Shanker joined Beam from Tevard Biosciences, where he served as CSO. Prior to Tevard, he spent eight years at Novartis Institutes for Biomedical Research, where he served as head of neuroscience, said the release by Beam Therapeutics.
“A key focus for me and my team will be progressing our base editing platform and evaluating potential new programs across each of our strategic pillars of haematology, immunology- oncology and genetic diseases,” Shanker said of his new role.
